Samsung Bioepis releases new data on five-year follow-up study of Ontruzant® (trastuzumab biosimilar)

Sep 13, 2021

Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with reference trastuzumab in early or locally advanced HER2 positive breast cancer. Samsung Bioepis reported that five year survival rates were 93.1% in the biosimilar trastuzumab group compared with 86.7% in the reference medicine group.

Print Page Mail Article